Nanosuspension based in situ gelling nasal spray of carvedilol: Development, in vitro and in vivo characterization

AAPS PharmSciTech

Volumn 14, Issue 1, 2013, Pages 189-199

  Saindane, Nilesh S ^a   Pagar, Kunal P ^a   Vavia, Pradeep R ^a  

^a INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

Author keywords

bioavailability; Carvedilol; in situ gel; intranasal; nanosuspension

Indexed keywords

CARVEDILOL; GELLAN; OLEIC ACID; POLOXAMER;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; DRUG FORMULATION; GELATION; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; NOSE MUCUS; PARTICLE SIZE; PHARMACOKINETICS; PRIORITY JOURNAL; SUSPENSION; SUSTAINED DRUG RELEASE; VISCOSITY; ZETA POTENTIAL;

ADMINISTRATION, INTRANASAL; ADRENERGIC ANTAGONISTS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL AVAILABILITY; CALORIMETRY, DIFFERENTIAL SCANNING; CARBAZOLES; FEMALE; GELS; MALE; MICROSCOPY, ELECTRON, SCANNING; NANOPARTICLES; POWDER DIFFRACTION; PROPANOLAMINES; RABBITS; VISCOSITY;

EID: 84878560549     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-012-9896-y     Document Type: Article

References (40)

1. Noriko N, Kimihiro N, Etsuo N. Antioxidant action of the antihypertensive drug carvedilol against lipid peroxidation. Biochem Pharmacol. 2000;59(9):1069-76. doi: 10.1016/S0006-2952(99)00417-7.
2. Mollendorff EV, Reiff K, Neugebauer G. Pharmacokinetics and bioavailability of carvedilol, a vasodilating beta-blocker. Eur J Clin Pharmacol. 1987;33(5):511-3. doi: 10.1007/BF00544245.
3. Hussain AA. Intranasal drug delivery. Adv Drug Deliv Rev. 1998;29(1-2):39-49. doi: 10.1016/S0169-409X(97)00060-4.
4. Turker S, Onur E, Ozer Y. Nasal route and drug delivery systems. Pharm World Sci. 2004;26(3):137-42. doi: 10.1023/B:PHAR.0000026823.82950.ff.
5. Suman JD. Nasal drug delivery. Expert Opin Biol Ther. 2003;3(3):519-23. doi: 10.1517/14712598.3.3.519.
6. Illum L. Nasal drug delivery-possibilities, problems and solutions. J Control Release. 2003;87(1-3):187-98. doi: 10.1016/S0168-3659(02)00363-2.
7. Ugwoke MI, Verbeke N, Kinget R. The biopharmaceutical aspects of nasal mucoadhesive drug delivery. J Pharm Pharmacol. 2001;53(1):3-22. doi: 10.1211/0022357011775145.
8. Michael IU, Remigius UA, Norbert V, Renaat K. Nasal mucoadhesive drug delivery: background, applications, trends and future perspectives. Adv Drug Deliv Rev. 2005;57(11):1640-65. doi: 10.1016/j.addr.2005.07.009.
9. Michael IU, Sam E, Guy VDM, Norbert V, Renaat K. Bioavailability of apomorphine following intranasal administration of mucoadhesive drug delivery systems in rabbits. Eur J Pharm Sci. 1999;9(2):213-9. doi: 10.1016/S0928- 0987(99)00061-5.
10. Zaki NM, Awad GA, Mortada ND, Abd. Elhady SA. Enhanced bioavailability of metoclopramide HCl by intranasal administration of a mucoadhesive in situ gel with modulated rheological and mucociliary transport properties. Eur J Pharm Sci. 2007;32(4-5):296-307. doi: 10.1016/j.ejps.2007.08.006.
11. Merkus FWHM, Schipper NGM, Hermens WAJJ, Romeijn SG, Verhoef JC. Absorption enhancers in nasal drug delivery: efficacy and safety. J Control Release. 1993;24(1-3):201-8. doi: 10.1016/0168-3659(93)90179-9.
12. Vyas TK, Babbar AK, Sharma RK, Singh S, Misra A. Intranasal mucoadhesive microemulsions of clonazepam: preliminary studies on brain targeting. J Pharm Sci. 2006;95(3):570-80. doi: 10.1002/jps.20480.
13. Amnon CS, Haim VL, Shafir B. Systemic delivery of insulin via the nasal route using a new microemulsion system: in vitro and in vivo studies. J Control Release. 2010;148(2):168-76. doi: 10.1016/j.jconrel.2010.08.004.
14. Lianli L, Indranil N, Kwon HM. Development of an ethyl laurate-based microemulsion for rapid-onset intranasal delivery of diazepam. Int J Pharm. 2002;237(1-2):77-85. doi: 10.1016/S0378-5173(02)00029-7.
15. Muller RH, Jacobs C. Buparvaquone mucoadhesive nanosuspension: preparation, optimisation and long-term stability. Int J Pharm. 2002;237(1-2):151-61. doi: 10.1016/S0378-5173(02)00040-6.
16. Dengning X, Peng Q, Hongze P, Hongyu P, Shaoping S, Yongmei Y, et al. Preparation of stable nitrendipine nanosuspensions using the precipitation-ultrasonication method for enhancement of dissolution and oral bioavailability. Eur J Pharm Sci. 2010;40(4):325-34. doi: 10.1016/j.ejps.2010. 04.006.
17. Shi-lei C, Xiao-wei R, Qi-zhi Z, En C, Feng X, Jun C, et al. In-situ gel based on gellan gum as new carrier for nasal administration of mometasone furoate. Int J Pharm. 2009;365(1-2):109-15. doi: 10.1016/j.ijpharm.2008.08.042.
18. Ito F, Fujimori H, Makino K. Factors affecting the loading efficiency of water-soluble drugs in PLGA microspheres. Colloids Surf B Biointerfaces. 2007;61(1):25-9. doi: 10.1016/j.colsurfb.2007.06.029.
19. Han CK, Bae YH. Inverse thermally-reversible gelation of aqueous N-isopropylacrylamide copolymer solutions. Polymer. 1998;39:2809-14.
20. Noha MZ, Gehanne AA, Nahed DM, Seham S, Abd E. Enhanced bioavailability of metoclopramide HCl by intranasal administration of a mucoadhesive in-situ gel with modulated rheological and mucociliary transport properties. Eur J Pharm Biopharm. 2007;32(4-5):296-307. doi: 10.1016/j.ejps.2007.08.006.
21. Callens C, Ceulemans J, Ludwig A, Foreman P, Remon JP. Rheological study on mucoadhesivity of some nasal powder formulations. Eur J Pharm Biopharm. 2003;55(3):323-8. doi: 10.1016/S0939-6411(03)00024-9.
22. Rowe RC, Sheskey PJ, Owen SC. Handbook of excipients. 2nd edn. UK; 2006. pp. 1120-1302.
23. Rajebahadur M, Zia H, Nues A, Lee C. Mechanistic study of solubility enhancement of nifedipine using vitamin E TPGS or Solutol HS-15. Drug Deliv. 2006;13(3):201-6. doi: 10.1080/10717540500316094.
24. Lennart L, Pia S, Urban S, Mikael R, Anna Z, Ulf O. Amorphous drug nanosuspensions. 1. Inhibition of Ostwald ripening. Langmuir. 2006;22(3):906-10. doi: 10.1021/la0523661.
25. Grau MJ, Kayser O, Muller RH. Nanosuspensions of poorly soluble drugs reproducibility for small scale production. Int J Pharm. 2000;196(2):155-9. doi: 10.1016/S0378-5173(99)00411-1.
26. Patravale VB, Date AA, Kulkarni RM. Nanosuspensions: a promising drug delivery strategy. J Pharm Pharmacol. 2004;56:827-40. doi: 10.1211/ 0022357023691.
27. Yuancai D, Wai KN, Shoucang S, Sanggu K, Reginald BHT. Preparation and characterization of spironolactone nanoparticles by antisolvent precipitation. Int J Pharm. 2009;375(1-2):84-8. doi: 10.1016/j.ijpharm.2009.03.013.
28. Bernard VE, Guy VM, Patrick A. Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products. Int J Pharm. 2008;364(1):64-75. doi: 10.1016/j.ijpharm.2008.07.023.
29. Kabalnov AS, Shchukin ED. Ostwald ripening theory: applications to fluorocarbon emulsion stability. Adv Colloid Interface Sci. 1992;38:69-97. doi: 10.1016/0001-8686(92)80043-W.
30. Kabalnov AS, Pertzov AV, Shchukin ED. Ostwald ripening in emulsions: I. Direct observations of Ostwald ripening in emulsions. Colloids Surfactant. 1987;118(2):590-7. doi: 10.1016/0021-9797(87)90492-9.
31. Heba FS. Sustained-release progesterone nanosuspension following intramuscular injection in ovariectomized rats. Int J Nanomedicine. 2010;5:943-54. doi: 10.2147/IJN.S12947.
32. Wei L, Yonggang Y, Yongshou T, Xinlan X, Yang C, Liwei M, et al. Preparation and in vitro/in vivo evaluation of revaprazan hydrochloride nanosuspension. Int J Pharm. 2011;408:157-62. doi: 10.1016/j.ijpharm.2011.01. 059.
33. Noyes A, Whitney W. The rate of solution of solid substances in their own solution. J Am Chem Soc. 1897;19:930-4.
34. Dhumal RS, Biradar SV, Yamamura, Paradkar AR, York P. Preparation of amorphous cefuroxime axetil nanoparticles by sonoprecipitation for enhancement of bioavailabilty. Eur J Pharm Biopharm. 2008;70(1):109-15. doi: 10.1016/j.ejpb.2008.04.001.
35. Buckton G, Beezer AE. The relationship between particle size and solubility. Int J Pharm. 1992;82(3):R7-10. doi: 10.1016/0378-5173(92)90184-4.
36. Dua R, Zia H, Needham T. The influence of tonicity and viscosity on the intranasal absorption of salmon calcitonin in rabbits. Int J Pharm. 1997;147(2):233-42. doi: 10.1016/S0378-5173(96)04817-X.
37. Hongyi Q, Wenwen C, Chunyan H, Li L, Chuming C, Wenmil L, et al. Development of a poloxamer analogs/carbopol-based in situ gelling and mucoadhesive ophthalmic delivery system for puerarin. Int J Pharm. 2007;337(1-2):178-87. doi: 10.1016/j.ijpharm.2006.12.038.
38. Grasdalen H, Smidsrod O. Gelation of gellan gum. Carbohydr Polym. 1987;7(5):371-93. doi: 10.1016/0144-8617(87)90004-X.
39. Hamid AM, Harris MS, Jaweria T. Once-daily tablet formulation and in vitro release evaluation of using hydroxypropyl methylcellulose: a technical note. AAPS PharmSciTech. 2003;7(3):E178-83. doi: 10.1208/pt070378.
40. Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm. 1983;15(1):25-35. doi: 10.1016/0378-5173(83)90064-9.